- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02407470
Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia
A Multicenter, Randomized, Controlled Study of the Efficacy and Safety of the Combination of Adipose Tissue-derived Hematopoietic Stem Cells (AD-HSCs) and ATG in the Treatment of Severe Aplastic Anemia
RATIONALE: It has been shown that about 30% of patients do not respond to immunosuppressive therapy or experience recurrence, and graft rejection and graft-versus-host-disease (GVHD) decrease event-free survival to 30% to 50% in the alternative donor (matched unrelated, partially matched family member) transplantation. Although an overall and disease free survival of 85% to 100%, can be obtained in allogeneic blood or bone marrow stem cell transplantation using an human leukocyte antigen (HLA) matched sibling donor, only about 25% of patients have such a donor.
PURPOSE: In an attempt to avoid GVHD, reduce earlier infection rate and decrease regimen-related toxicity while maintaining better engraftment, this study is to evaluate the effectiveness and safety of patient's own adipose-derived mesenchymal stem cell (AD-MSC) or AD-MSC transdifferentiated HSC (AD-HSC) transplant after an immunosuppressive regimen in treating patients who have severe aplastic anemia.
The patient will be in the study for one year for observation and active monitoring. After treatment and active monitoring are over, the patient's medical condition will be followed indefinitely. The principle measures of safety and efficacy will be :
- Patient survival probability at 3 months, 6 months and 1 year.
- Engraftment at 3 months, 6 months and 1 year
- Incidence of graft versus host disease (GVHD), incidence of acute and chronic GVHD and Incidence of earlier infection rate as well as other complications within 6 months and 1 years.
Study Overview
Status
Conditions
Detailed Description
Severe aplastic anemia is characterized by severe deficiencies in peripheral-blood platelets, white cells, and red cells. These defects in mature cells occur because aplastic bone marrow contains severely reduced numbers of hematopoietic stem cells. To date, Hematopoietic stem cell (HSC) transplants are routinely used to treat patients with many different diseases, including various cancers and blood disorders, such as aplastic anemia. The main sources of HSCs are bone marrow, cord blood and peripheral blood. However, challenges include obtaining enough functional HSCs to ensure optimal engraftment, and avoiding immune rejection and other complications associated with allogeneic transplantations. Novel abundant sources of clinical-grade HSCs are therefore being sought.
Our novel studies have demonstrated that adipose-derived mesenchymal stem cells (AD-MSCs) can be converted rapidly (in 4 days) into AD-HSCs on a large scale (2X108-9 cluster of differentiation 34(CD34)positive cells) by transfection of small RNAs to the the early region 1A (E1A)-like inhibitor of differentiation 1 (EID1) in the presence of specific cytokines. In vitro, AD-HSCs expanded efficiently and resembled cord-blood HSCs in phenotype, genotype, and colony-forming ability. In a mouse model, primary and secondary transplantation analysis and repopulating assays showed that AD-HSCs homed to the bone marrow, differentiated into functional blood cells, and showed a long-term ability to self-renew. we show that adipose-derived mesenchymal stem cells (AD-MSCs) can be converted into AD-HSCs by transfection of small RNAs to the E1A-like inhibitor of differentiation 1 (EID1) in the presence of specific cytokines. In vitro, AD-HSCs expanded efficiently and resembled cord-blood HSCs in phenotype, genotype, and colony-forming ability. In a mouse model, primary and secondary transplantation analysis and repopulating assays showed that AD-HSCs homed to the bone marrow, differentiated into functional blood cells, and showed a long-term ability to self-renew. In the safety aspect, we saw no evidence of leukemia, teratoma and other cancers in the blood, testes and subcutaneous tissues of transplanted mice. More importantly, our preliminary data have shown that AD-HSCs can reconstitute hematopoietic function in five patients with severe aplastic anemia. Based on these premilitary studies,, we have determined to conduct a further clinical investigation in multiple medical centers. In this study we plan to enroll up to 90 patients, to make a comprehensive assessment for this new treatment regimen and to show it is equal or superior to the current immunosuppressive regimen. Patients will be in the study for one years for treatment and active monitoring. All patients will be followed until death.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: James Q Yin, M.D.,Ph.D.
- Phone Number: 86-01-84008003
- Email: Jamesyin2010@126.com
Study Contact Backup
- Name: Jianliang Shen, M.D.,Ph.D.
- Phone Number: 86-01-66957676
- Email: nghxyk@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100048
- Recruiting
- Navy General Hospital
-
Contact:
- Jianliang Shen, M.D.,Ph.D
- Phone Number: 86-01-66957676
- Email: nghxyk@163.com
-
Contact:
- Qinwei Yin, M.D.,Ph.D.
- Phone Number: 86-01-84008003
- Email: jamesyin2010@126.com
-
Principal Investigator:
- James Yin, M.D.,Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or female recipients must have histopathologically confirmed diagnosis of SAA-I without or with more than 6 months after less than one treatment with ATG. Diagnostic Criteria for Server Aplastic Anemia will be based on the definitions set forth by the international Aplastic Anemia Study Group.
At least two of the following:
Absolute neutrophil count ≤ 0.5 X 109/l, Platelet count ≤ 20 X 109 /l, Anemia with corrected reticulocyte count ≤ 1%, and Bone marrow cellularity ≤ 25%, or bone marrow cellularity ≤ 50% with fewer than 30% hematopoietic cell, Hepatic: alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) no greater than 4 times normal, Bilirubin: no greater than 2 mg/dl, Renal: Creatinine clearance at least 50 ml/min, Cardiovascular: Shortening fraction or ejection fraction at least 40% of normal for age by echocardiogram or radionuclide scan.
No clinically significant comorbid illnesses (e.g., myocardial infarction or cerebrovascular accident).
Exclusion Criteria:
Active and uncontrolled infection, Active bleeding, Severe allergic history of ATG, HIV-1 infection, Pregnancy or breastfeeding, Carbon monoxide lung diffusion capacity (DLCO) <40% predicted, SAA-II, Patients with severe psychological disorders, Recipients of other clinical trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Rabbit antithymoglobulin (ATG)
Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.
|
Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
Other Names:
|
EXPERIMENTAL: Rabbit ATG & AD-MSCs
Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.
|
Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
Other Names:
Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
Other Names:
|
EXPERIMENTAL: Rabbit ATG & AD-HSCs
Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4.
|
Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
Other Names:
Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engraftment at 42 days post AD-HSC transplantation for patients with severe aplastic anemia.
Time Frame: 42 days posttransplant
|
Absolute neutrophil count > 0.5 X 109/l and Platelet count > 20 X 109 /l without infusion of platelet for 7 days.
|
42 days posttransplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To estimate the overall survival (OS) at 1 year following AD-HSC transplantation for Patients with Severe Aplastic Anemia
Time Frame: 1 year
|
Number of Subjects Alive at 12 months Post Transplant
|
1 year
|
Relapse
Time Frame: 1 year post transplant
|
Return of SAA during the specified post-transplantation period.
|
1 year post transplant
|
Incidence of chronic graft-versus-host disease
Time Frame: 6 months
|
Number of patients with chronic graft-versus-host disease by 6 months and 1 year
|
6 months
|
Evaluation of the occurrence of secondary malignancies
Time Frame: 6 months post transplant
|
Occurring of any tumors during the specified post-transplantation period.
|
6 months post transplant
|
Hematology labs
Time Frame: 12 weeks
|
Association between AD-HSC transplantation and response in hemoglobin, platelet, total white blood cell count, and absolute neutrophil count to be evaluate by maximal hemoglobin, platelet, total white blood cell count, and absolute neutrophil counts achieved in patients with severe aplastic anemia
|
12 weeks
|
Number of participants with adverse events as a measure of safety and tolerability of intravenous AD-HSC infusion in patients with severe aplastic anemia
Time Frame: weekly untill 12 months
|
Adverse events like allergic reactions, infectious diseases, organ dysfunction or other related to AD-HSC infusion will be assessed
|
weekly untill 12 months
|
Transfusional requirements
Time Frame: weekly untill 6 months
|
Units of blood or platelets transfused after AD-HSC infusion will be measured and compared to previously.
|
weekly untill 6 months
|
To assess treatment related mortality
Time Frame: 12 months
|
Number of death after transplantation during the specified post-transplantation period.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: james Q Yin, M.D.,Ph.D., The military general hospital of Beijing
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ginkgocell-ADHSC-AA-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Aplastic Anemia
-
University of UtahNovartisCompletedSevere Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic AnemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Severe Aplastic Anemia | Refractory Severe Aplastic AnemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedSevere Aplastic Anemia, Refractory | Severe Aplastic Anemia, RelapseUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Peking University People's HospitalRecruiting
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingSevere Aplastic AnemiaUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other collaboratorsCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedSevere Aplastic Anemia (SAA)United States
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedSevere Aplastic Anemia (SAA)United States
Clinical Trials on Rabbit antithymoglobulin (ATG)
-
National Institute of Blood Disease Center, PakistanUnknown
-
Shanghai General Hospital, Shanghai Jiao Tong University...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownAcute Lymphoblastic Leukemia | Lymphoblastic LymphomaChina
-
Gang ChenChanghai Hospital; First Affiliated Hospital, Sun Yat-Sen University; The First... and other collaboratorsCompletedKidney Transplant Rejection | Pediatric Kidney DiseaseChina
-
The Methodist Hospital Research InstituteUnknownAcute (Cellular) Renal Allograft RejectionUnited States
-
Ohio State University Comprehensive Cancer CenterCelgene CorporationRecruitingCutaneous T-cell Lymphoma | Peripheral T-Cell Lymphoma | T-Prolymphocytic Leukemia | T-Large Granulocytic Leukemia | T-Lymphoblastic Leukemia/LymphomaUnited States
-
Universitaire Ziekenhuizen KU LeuvenActive, not recruitingDiabetes Mellitus, Type 1Belgium, Austria, Slovenia, Denmark, United Kingdom, Italy, Finland, Germany
-
M.D. Anderson Cancer CenterCompletedLymphoma | LeukemiaUnited States
-
Novartis PharmaceuticalsCompleted
-
Chinese PLA General HospitalRecruiting
-
Neovii BiotechCompletedMyelodysplastic Syndrome | GVHD | Adult Acute Myeloid Leukemia | Adult Acute Lymphoid LeukemiaUnited States, Australia